BioMed Research International

Research Article

KIR3DL1 and HLA-Bw4 Interaction Showed a Favorable Role in Patients with Myelodysplastic Syndromes in Chinese Southern Han

Table 2

Comparison analysis for class I HLA ligands and KIR-HLA combinations between MDS patients and controls.
Patients
(%)		Controls
(%)		OR (95% CI)
HLA ligands    
 C1/C1 vs.52 (72.22)520 (72.22)1.000 (0.582-1.718)1.000
 C1/C220 (27.78)200 (27.78)  
 C1/C1 vs.52 (92.86)520 (97.38)0.350 (0.111-1.102)0.810
 C2/C24 (7.14)14 (2.62)  
 C1/C2 vs.20 (83.33)200 (93.46)0.350 (0.105-1.165)0.092
 C2/C24 (16.67)14 (6.54)  
 C1+vs.72 (94.74)720 (98.09)0.350 (0.112-1.091)0.079
 C2/C24 (5.26)14 (1.91)  
 C2+vs.24 (31.58)214 (29.16)1.121 (0.674-1.866)0.659
 C1/C152 (68.42)520 (70.84)  
 Bw4 vs.48 (62.34)547 (73.42)0.599 (0.367-0.977)0.038
 Others29 (37.66)198 (26.58)  
 Bw4-80I vs.31 (40.26)404 (54.23)0.569 (0.353-0.917)0.019
 Others46 (59.74)341 (45.77)  
 Bw4-80T vs.27 (35.06)246 (33.02)1.095 (0.669-1.792)0.717
 Others50 (64.94)499 (66.98)  
 A3/A1149 (63.64)450 (60.57)1.139 (0.700-1.854)0.599
 Others28 (36.36)293 (39.43)  
KIR-HLA combinations    
 3DL1-Bw4 vs.46 (59.74)528 (70.87)0.610 (0.377-0.988)0.043
 Others31 (40.26)217 (29.13)  
 3DL1-Bw4-80I vs.29 (37.66)392 (52.62)0.544 (0.336-0.882)0.012
 Others48 (62.34)353 (47.38)  
 3DL1-Bw4-80T vs.22 (28.57)238 (31.95)0.852 (0.508-1.430)0.544
 Others55 (71.43)507 (68.05)  
 3DS1-Bw4 vs.16 (20.78)166 (22.28)0.915 (0.514-1.629)0.762
 Others61 (79.22)579 (77.72)  
 2DL1-C2 vs.24 (31.58)213 (29.02)1.129 (0.678-1.879)0.641
 Others52 (68.42)521 (70.98)  
2DS1-C2 vs.8 (10.53)70 (9.54)1.116 (0.515-2.417)0.781
 Others68 (89.47)664 (90.46)  
 2DL2-C1 vs.18 (23.68)154 (20.98)1.169 (0.669-2.042)0.583
 Others58 (76.32)580 (79.02)  
 2DL3-C1 vs.71 (93.42)709 (96.59)0.501 (0.186-1.348)0.190
 Others5 (6.58)25 (3.41)  
 2DS2-C1 vs.18 (23.68)154 (20.98)1.169 (0.669-2.042)0.583
 Others58 (76.32)580 (79.02)  
Note: C1+ includes C1/C1 and C1/C2 genotypes, C2+ includes C1/C2 and C2/C2 genotypes.